IVOSIDENIB-CHONDRO-LT

NCT02073994 📎

Regimen

Experimental
Ivosidenib 500 mg QD continuous, median treatment duration extended to multi-year for durable responders
Control
none

Population

Same cohort as NCT02073994 chondrosarcoma expansion: advanced IDH1-mutant conventional chondrosarcoma, long-term follow-up update

Key finding

Long-term follow-up confirms durable disease stabilization in a meaningful minority of IDH1-mutant chondrosarcoma patients. Established ivosidenib as a reasonable biomarker-selected option in a setting with no standard therapy.

Source: PMID 40100120

Timeline

    Guideline citations

    • NCCN BONE (p.10)